Yahoo Finance Insider Sell: VP, Chief Accounting Officer Chad Winters Sells Shares of West Pharmaceutical ...
West Pharmaceutical Services Inc (NYSE:WST), a global leader in the design and production of containment and delivery systems for injectable drugs and healthcare products, has reported an insider sell according to a recent SEC filing. Chad Winters, the company's Vice President and Chief Accounting Officer, sold 815 shares of the company on March 11, 2024.The transaction was executed at an average price of $358.82 per share, resulting in a total sale amount of $292,438.30. Following this transaction, the insider's stake in West Pharmaceutical Services Inc has been adjusted as per the latest SEC filings.Over the past year, Chad Winters has sold a total of 2,841 shares of West Pharmaceutical Services Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of more insider sales than buys over the past year, with 19 insider sells and no insider buys recorded during this period.
The stock's market cap stands at $27.241 billion as of the day of the insider's recent sale. With a price-earnings ratio of 47.16, West Pharmaceutical Services Inc's valuation is higher than the industry median of 27.945 and also exceeds the company's historical median price-earnings ratio.Considering the stock's price of $358.82 and the GuruFocus Value of $380.30, West Pharmaceutical Services Inc has a price-to-GF-Value ratio of 0.94, indicating that the stock is Fairly Valued based on its GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
Investors and analysts often monitor insider transactions as they can provide insights into the company's performance and insider perspectives on the stock's valuation. The recent sell by Chad Winters may attract attention from the market as stakeholders consider the implications of such insider activities.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
